Business Wire

Deenova Wins New Italian Public Tender at IRCCS Policlinico San Matteo in Pavia, Lombardy

31.5.2022 07:00:00 EEST | Business Wire | Press release

Share

Deenova reported today it recently beat its main competitors and was awarded a public tender for IRCCS Policlinico San Matteo named “Open telematic procedure for the acquisition of an integrated information system for the management of drug therapy and the traceability of drugs and medical devices” by decree of the General Manager No. 5/D.G./334 as of March 18, 2022. This new Deenova customer in Italy includes the implementation and services for its many clinicians utilization at the point of care of 100 prescription trolleys, 100 administration trolleys, 100 barcode readers, 200 portable PCs, and 100 label printers.

Fulvio Rudello, Chief Operating Officer at Deenova stated: “This IRCCS Policlinico San Matteo is another testament of Deenova´s Closed-Loop solutions undisputed European leadership in the healthcare industry. It cements the economic balance of continuing to add net new customers in Europe while at the same time proudly show a 100% retention rate of our existing customers, metrics that have no parallel in the health care sector.”

The IRCCS Policlinico San Matteo in Pavia has over 1,000 accredited beds serving 700.000 inhabitants in Lombardy, divided into about 60 operating units with teaching, health care assistance, and research activities. Among its units there are many areas of excellence, with approximately about 3,300 employees including doctors, nurses, technicians and administrators, offering 36,500 hospitalizations (13.7% of which to patients outside the region), 99.000 emergency room visits and 2.1 million outpatient visits.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Christophe Jaffuel, Martina Buccianti
m.buccianti@deenova.com, +39 0523 785311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Cutting-Edge Research to Industry: Focused Energy Plans Spin-Off of Sourcelight10.6.2026 12:38:00 EEST | Press release

Following its successful USD 240 million financing round, Focused Energy is continuing to systematically advance the industrialization of laser fusion as its core business. At the same time, the company plans to consolidate its activities in the field of laser-driven radiation sources into an independent entity under the name Sourcelight. With this move, Focused Energy is laying the groundwork for the industrial transfer of selected technological building blocks emerging from its laser fusion development. The spin-off demonstrates how cutting-edge research can give rise to new industry: scientific excellence is translated into industrial applications with strong value creation and growth potential. Sourcelight is intended to bring the LDRS (Laser-Driven Radiation Sources) technology developed by Focused Energy into targeted industrial applications. The technology combines laser-driven high-energy X-rays and neutrons in a single system. This enables not only high-resolution imaging, but

Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems10.6.2026 12:30:00 EEST | Press release

Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT's international market access and business development. By combining Cosylab's proven expertise in mission-critical software and complex system integration with Heron's end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality. "AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologie

GlobalFoundries and Qualinx Demonstrate First European Sovereign Manufacturing Flow for Security‑Critical Semiconductors10.6.2026 12:25:00 EEST | Press release

GlobalFoundries (GF) and Qualinx today announced the successful completion of the first fully European-based, end-to-end semiconductor manufacturing flow at GlobalFoundries’ Dresden fab on its FDX technology. The milestone demonstrates that security-critical chips for aerospace, defence and critical infrastructure can be designed, manufactured and delivered entirely within Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610196220/en/ In this partnership, Qualinx served as the launch customer with a sophisticated GNSS SoC design for secure Positioning, Navigation and Timing (PNT) applications. The QLX3xx design targets sovereign GNSS-based PNT solutions for aerospace, defence and critical infrastructures—such as resilient timing and synchronization networks and highly integrated, ultra-low-power GNSS receivers at the connected edge. GF and Qualinx Set a Benchmark for GF’s European Sovereign Manufacturing co-funded b

LTM Introduces BlueVerse™ Currency to Enable Outcome-Based Pricing in the Agentic AI Era10.6.2026 11:30:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today introduced BlueVerse™ Currency, an AI-linked commercial model that prices enterprise work by outcomes rather than effort consumed as enterprises scale agentic AI across core processes. BlueVerse Currency brings together the full BlueVerse stack—People (expertise on demand), Accelerators (reusable assets that speed delivery), Agents (autonomous AI workforce), Platforms (orchestration layer to scale delivery), and Tokens (compute and model usage)—into a single commercial construct. It introduces outcome-linked pricing tied to measurable business results, enabling shared productivity gains so clients can capture AI-driven efficiency value. The model also supports fungible resourcing, enabling reallocation mid-contract to evolving priorities, and faster reinvestment, with savings redirected into innovation. It is underpinned by a hybrid structure with fixed and variable pricing components, supported by use-case–

Smead Capital Management Extends International Value Strategy to Global Investors Through New Fund10.6.2026 10:00:00 EEST | Press release

Smead Capital Management, a Phoenix-based investment management firm and a leader in value investing, today announced the launch of the Smead Global ex-US Value UCITS Fund designed to provide global investors with access to a product modeled after the firm’s long-standing Smead International Value Strategy. The Smead Global ex-US Value UCITS Fund is domiciled in Luxembourg. Investors can access the fund through Smead Capital Management’s website and it is available to professional and qualified investors through the fund’s transfer agent. The strategy that the Smead Global ex-US Value UCITS Fund is modeled after, the Smead International Value Strategy, has been a core contributor to Smead Capital Management’s outstanding performance for over a decade. Like all Smead products, the Global ex-US Value UCITS Fund will be built on Smead’s eight investment criteria and a disciplined, contrarian, value approach. “Many investors around the world believe non-US companies cannot produce attracti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye